These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38773801)

  • 1. Temporal trends in use of antisecretory agents among patients administered clopidogrel-based dual antiplatelet therapy after percutaneous coronary intervention.
    Lee Y; Choi HJ; Park S; Je NK
    Pharmacoepidemiol Drug Saf; 2024 Jun; 33(6):e5816. PubMed ID: 38773801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
    Harvey A; Modak A; Déry U; Roy M; Rinfret S; Bertrand OF; Larose É; Rodés-Cabau J; Barbeau G; Gleeton O; Nguyen CM; Proulx G; Noël B; Roy L; Paradis JM; De Larochellière R; Déry JP
    J Breath Res; 2016 Jan; 10(1):017104. PubMed ID: 26815196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy.
    Yamane K; Kato Y; Tazaki J; Tada T; Makiyama T; Imai M; Jinnai T; Ikeda T; Shirakawa R; Kimura T; Horiuchi H
    J Atheroscler Thromb; 2012; 19(6):559-69. PubMed ID: 22472213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial.
    Vaduganathan M; Cannon CP; Cryer BL; Liu Y; Hsieh WH; Doros G; Cohen M; Lanas A; Schnitzer TJ; Shook TL; Lapuerta P; Goldsmith MA; Laine L; Bhatt DL;
    Am J Med; 2016 Sep; 129(9):1002-5. PubMed ID: 27143321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of proton pump inhibitor use on clinical outcomes in East Asian patients receiving clopidogrel following drug-eluting stent implantation.
    Kim JH; Hong SJ; Cha JJ; Lim S; Joo HJ; Park JH; Yu CW; Ahn TH; Jeong YH; Kim BK; Chang K; Park Y; Song YB; Ahn SG; Suh JW; Lee SY; Cho JR; Her AY; Kim HS; Kim MH; Shin ES; Lim DS
    BMC Med; 2024 Aug; 22(1):335. PubMed ID: 39148087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
    Sibbing D; Morath T; Stegherr J; Braun S; Vogt W; Hadamitzky M; Schömig A; Kastrati A; von Beckerath N
    Thromb Haemost; 2009 Apr; 101(4):714-9. PubMed ID: 19350116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel.
    Morneau KM; Reaves AB; Martin JB; Oliphant CS
    J Manag Care Pharm; 2014 Feb; 20(2):187-93. PubMed ID: 24456320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
    Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding.
    Tsai YW; Wen YW; Huang WF; Chen PF; Kuo KN; Hsiao FY
    J Gastroenterol; 2011 Jan; 46(1):39-45. PubMed ID: 20811753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent concurrent use of clopidogrel and proton pump inhibitors did not increase risk of adverse clinical outcomes in Chinese patients with coronary artery disease.
    He W; Shu X; Zhu E; Deng B; Lin Y; Wu X; Zhou Z; Wang J; Nie R
    BMC Cardiovasc Disord; 2021 Feb; 21(1):75. PubMed ID: 33546595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of esomeprazole vs famotidine on aspirin/clopidogrel dual therapy after percutaneous coronary intervention.
    Wu Y; Chen C; Luo Y; Yu W; Huang S; Lin D
    Adv Clin Exp Med; 2019 Nov; 28(11):1519-1524. PubMed ID: 31660706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clopidogrel with or without omeprazole in coronary artery disease.
    Bhatt DL; Cryer BL; Contant CF; Cohen M; Lanas A; Schnitzer TJ; Shook TL; Lapuerta P; Goldsmith MA; Laine L; Scirica BM; Murphy SA; Cannon CP;
    N Engl J Med; 2010 Nov; 363(20):1909-17. PubMed ID: 20925534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Esomeprazole and rabeprazole did not reduce antiplatelet effects of aspirin/clopidogrel dual therapy in patients undergoing percutaneous coronary intervention: a prospective, randomized, case-control study.
    Liu LP; Wang Y; Si R; Yuan M; Cheng K; Guo WY
    Expert Opin Pharmacother; 2016; 17(1):7-16. PubMed ID: 26549402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant use of proton pump inhibitors and dual antiplatelet therapy for cardiovascular outcomes.
    Mandurino-Mirizzi A; Leonardi S; Melloni C
    Minerva Endocrinol; 2017 Sep; 42(3):228-237. PubMed ID: 27808485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitors and other disease-based factors in the recurrence of adverse cardiovascular events following percutaneous coronary angiography: A long-term cohort.
    Ayub A; Parkash O; Naeem B; Murtaza D; Khan AH; Jafri W; Hamid S
    Indian J Gastroenterol; 2016 Mar; 35(2):117-22. PubMed ID: 27056735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
    Vaduganathan M; Bhatt DL; Cryer BL; Liu Y; Hsieh WH; Doros G; Cohen M; Lanas A; Schnitzer TJ; Shook TL; Lapuerta P; Goldsmith MA; Laine L; Cannon CP;
    J Am Coll Cardiol; 2016 Apr; 67(14):1661-71. PubMed ID: 27012778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethnic variance on long term clinical outcomes of concomitant use of proton pump inhibitors and clopidogrel in patients with stent implantation: A PRISMA-complaint systematic review with meta-analysis.
    Shi W; Yan L; Yang J; Yu M
    Medicine (Baltimore); 2021 Feb; 100(6):e24366. PubMed ID: 33578533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet inhibitory effect of clopidogrel in patients treated with omeprazole, pantoprazole, and famotidine: a prospective, randomized, crossover study.
    Arbel Y; Birati EY; Finkelstein A; Halkin A; Kletzel H; Abramowitz Y; Berliner S; Deutsch V; Herz I; Keren G; Banai S
    Clin Cardiol; 2013 Jun; 36(6):342-6. PubMed ID: 23630016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clopidogrel and proton pump inhibitors: is there a significant drug-drug interaction?
    Shmulevich E; Friger M; Gilutz H; Azab AN
    Can J Cardiovasc Nurs; 2011; 21(4):27-36. PubMed ID: 22165503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
    Gargiulo G; Costa F; Ariotti S; Biscaglia S; Campo G; Esposito G; Leonardi S; Vranckx P; Windecker S; Valgimigli M
    Am Heart J; 2016 Apr; 174():95-102. PubMed ID: 26995375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.